Teleflex (NYSE:TFX) Upgraded by Wall Street Zen to "Strong-Buy" Rating

Key Points

• Teleflex has been upgraded to a "strong-buy" rating by Wall Street Zen, indicating increasing confidence from analysts after previous ratings of "buy" and "hold."
• Teleflex reported $3.73 earnings per share for the last quarter, exceeding analysts' expectations and showcasing a 4.2% year-over-year revenue growth.
• Institutional investors are actively increasing their stake in Teleflex, with significant purchases made by Norges Bank and Dimensional Fund Advisors, highlighting strong institutional interest.

Teleflex (NYSE:TFX - Get Free Report) was upgraded by analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating in a research report issued to clients and investors on Sunday.

Other equities research analysts have also issued research reports about the stock. Royal Bank Of Canada boosted their price target on shares of Teleflex from $130.00 to $135.00 and gave the company a "sector perform" rating in a report on Friday, August 1st. Mizuho boosted their price target on shares of Teleflex from $130.00 to $135.00 and gave the company a "neutral" rating in a report on Friday, August 1st. Finally, Wells Fargo & Company reduced their price target on shares of Teleflex from $137.00 to $131.00 and set an "equal weight" rating for the company in a report on Friday, August 1st. One investment analyst has rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Teleflex currently has an average rating of "Hold" and a consensus price target of $141.57.

Teleflex Trading Up 1.2%

Shares of TFX opened at $130.62 on Friday. Teleflex has a 1-year low of $108.90 and a 1-year high of $249.90. The company has a 50-day moving average of $119.91 and a 200 day moving average of $127.67. The firm has a market capitalization of $5.77 billion, a price-to-earnings ratio of 30.73, a PEG ratio of 1.82 and a beta of 1.08. The company has a debt-to-equity ratio of 0.42, a current ratio of 2.41 and a quick ratio of 1.44.

Teleflex (NYSE:TFX - Get Free Report) last announced its quarterly earnings data on Thursday, July 31st. The medical technology company reported $3.73 earnings per share for the quarter, beating analysts' consensus estimates of $3.36 by $0.37. Teleflex had a net margin of 6.31% and a return on equity of 15.08%. The company had revenue of $780.90 million during the quarter, compared to analyst estimates of $771.53 million. During the same quarter last year, the business posted $3.42 EPS. The firm's revenue for the quarter was up 4.2% on a year-over-year basis. Teleflex has set its FY 2025 guidance at 13.900-14.300 EPS. On average, research analysts expect that Teleflex will post 13.98 EPS for the current year.

Insider Transactions at Teleflex

In other news, Director Andrew A. Krakauer acquired 1,000 shares of the business's stock in a transaction dated Tuesday, August 5th. The shares were purchased at an average price of $115.25 per share, with a total value of $115,250.00. Following the transaction, the director directly owned 7,192 shares in the company, valued at approximately $828,878. This represents a 16.15% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Liam Kelly acquired 1,500 shares of the business's stock in a transaction dated Tuesday, August 5th. The stock was purchased at an average cost of $115.07 per share, for a total transaction of $172,605.00. Following the transaction, the chief executive officer owned 45,267 shares in the company, valued at approximately $5,208,873.69. The trade was a 3.43% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders have bought 5,500 shares of company stock worth $633,590. 1.40% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of TFX. Norges Bank purchased a new position in shares of Teleflex in the 2nd quarter worth approximately $65,826,000. Pzena Investment Management LLC acquired a new stake in Teleflex in the 2nd quarter worth approximately $42,149,000. Dimensional Fund Advisors LP boosted its stake in Teleflex by 69.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 867,864 shares of the medical technology company's stock worth $119,927,000 after purchasing an additional 355,720 shares in the last quarter. Diamond Hill Capital Management Inc. boosted its stake in Teleflex by 122.8% in the 1st quarter. Diamond Hill Capital Management Inc. now owns 584,586 shares of the medical technology company's stock worth $80,784,000 after purchasing an additional 322,222 shares in the last quarter. Finally, Invenomic Capital Management LP boosted its stake in Teleflex by 1,400.1% in the 1st quarter. Invenomic Capital Management LP now owns 344,732 shares of the medical technology company's stock worth $47,639,000 after purchasing an additional 321,751 shares in the last quarter. Hedge funds and other institutional investors own 95.62% of the company's stock.

Teleflex Company Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.